| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5581773 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 26 Pages |
Abstract
Low-dose (eg, ⤠20 mg) dasatinib therapy generates an adequate molecular response in most elderly patients with chronic phase CML without causing severe AEs.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Hidekazu Itamura, Yasushi Kubota, Takero Shindo, Toshihiko Ando, Kensuke Kojima, Shinya Kimura,